These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35907664)

  • 1. Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer.
    Vilaseca A; Ribal MJ
    Eur Urol; 2022 Nov; 82(5):573. PubMed ID: 35907664
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer.
    Chen K; McVey A; Kasivisvanathan V; Jenjitranant P; Azad A; Murphy DG
    Eur Urol; 2022 Jul; 82(1):146-147. PubMed ID: 35346516
    [No Abstract]   [Full Text] [Related]  

  • 3. Darolutamide in hormone-sensitive and castration-resistant prostate cancer.
    Palmieri VE; Roviello G; D'Angelo A; Casadei C; De Giorgi U; Giorgione R
    Expert Rev Clin Pharmacol; 2021 May; 14(5):535-544. PubMed ID: 33685318
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K; Smith MR; Tombal B
    Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A new androgen receptor antagonist : Darolutamide for patients with non-metastatic castration-resistant prostate cancer].
    Kesch C; Hadaschik BA
    Urologe A; 2019 Oct; 58(10):1217-1218. PubMed ID: 31471641
    [No Abstract]   [Full Text] [Related]  

  • 6. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
    Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH
    Molecules; 2020 May; 25(10):. PubMed ID: 32456317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An up-to-date evaluation of darolutamide for the treatment of prostate cancer.
    Moussa M; Lazarou L; Dellis A; Abou Chakra M; Papatsoris A
    Expert Opin Pharmacother; 2021 Mar; 22(4):397-402. PubMed ID: 33135506
    [No Abstract]   [Full Text] [Related]  

  • 8. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.
    Smith MR; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford D; Manarite J; Muslin D; Farrington T; Tombal B
    Future Oncol; 2022 Jul; 18(21):2585-2597. PubMed ID: 35656777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
    Zhang F; Lu YP
    Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cases in the management of prostate cancer: the addition of darolutamide to androgen deprivation therapy and docetaxel in a 55-year-old man with metastatic hormone-sensitive prostate cancer.
    Crawford ED
    Clin Adv Hematol Oncol; 2022 Jul; 20 Suppl 14(7):1-8. PubMed ID: 35905311
    [No Abstract]   [Full Text] [Related]  

  • 12. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
    Fizazi K; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Le Berre MA; Petrenciuc O; Snapir A; Sarapohja T; Smith MR;
    N Engl J Med; 2020 Sep; 383(11):1040-1049. PubMed ID: 32905676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer.
    Alghazo O; Thangasamy I; Sathianathen N; Murphy DG
    Eur Urol; 2019 Oct; 76(4):536-537. PubMed ID: 31101535
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
    Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darolutamide for treatment of castration-resistant prostate cancer.
    Rhea LP; Mendez-Marti S; Aragon-Ching JB
    Drugs Today (Barc); 2020 Mar; 56(3):185-193. PubMed ID: 32282865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Androgen receptor inhibitors in prostate cancer: new drugs, but for which patient?].
    Vis AN; van Moorselaar RJA
    Ned Tijdschr Geneeskd; 2019 Nov; 163():. PubMed ID: 32073798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cases in the management of nonmetastatic castration-resistant prostate cancer: darolutamide added to leuprolide in a 73-year-old patient.
    Landau DA
    Clin Adv Hematol Oncol; 2022 Jun; 20 Suppl 10(6):1-8. PubMed ID: 35772002
    [No Abstract]   [Full Text] [Related]  

  • 18. Darolutamide: First Approval.
    Markham A; Duggan S
    Drugs; 2019 Nov; 79(16):1813-1818. PubMed ID: 31605368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Darolutamide (ODM-201) for the treatment of prostate cancer.
    Shore ND
    Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
    Fizazi K; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Kappeler C; Snapir A; Sarapohja T; Smith MR;
    N Engl J Med; 2019 Mar; 380(13):1235-1246. PubMed ID: 30763142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.